NCT07228832
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07228832
Title Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer ((HARMONi-GI3))
Acronym HARMONi-GI3
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Summit Therapeutics
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Clinical Study Site RECRUITING Cerritos California 90703 United States Details
Clinical Study Site RECRUITING Los Angeles California 90067 United States Details
Clinical Study Site RECRUITING Murrieta California 92562 United States Details
Clinical Study Site RECRUITING Hialeah Florida 33013 United States Details
Clinical Study Site RECRUITING Port Saint Lucie Florida 34952 United States Details
Clinical Study Site RECRUITING O'Fallon Illinois 62269 United States Details
Clinical Study Site RECRUITING Saint Louis Park Minnesota 55426 United States Details
Clinical Study Site RECRUITING Lincoln Nebraska 68506 United States Details
Clinical Study Site RECRUITING Spokane Washington 99208 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field